JD-30, an active fraction extracted from Danggui-Shaoyao-San, decreases β-amyloid content and deposition, improves LTP reduction and prevents spatial cognition impairment in SAMP8 mice

Experimental Gerontology

Volumn 47, Issue 1, 2012, Pages 14-22

  Hu, Zeng Yao ^a   Liu, Gang ^a   Cheng, Xiao Rui ^a   Huang, Yan ^a   Yang, Sheng ^a   Qiao, Shan Yi ^a   Sun, Lei ^a   Zhou, Wen Xia ^a   Zhang, Yong Xiang ^a  

^a BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

amyloid (A ); Alzheimer's disease (AD); Danggui Shaoyao San (DSS); JD 30; Long term potentiation (LTP); Senescence accelerated mouse prone 8 (SAMP8); Spatial learning and memory

Indexed keywords

AMYLOID BETA PROTEIN; JD 30; PLANT MEDICINAL PRODUCT; TOKISHAKUYAKU SAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; FEMALE; HIPPOCAMPUS; LEARNING DISORDER; LONG TERM CARE; LONG TERM POTENTIATION; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NERVE CELL LESION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONTENT; SPATIAL MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BRAIN CHEMISTRY; COGNITION DISORDERS; DRUGS, CHINESE HERBAL; ELECTROPHYSIOLOGICAL PHENOMENA; FEMALE; GENE EXPRESSION; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; MAZE LEARNING; MEMORY; MICE; MICE, INBRED STRAINS; SPATIAL BEHAVIOR;

DANGGUI; MUS; RODENTIA;

EID: 84155172500     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2011.09.009     Document Type: Article

References (38)

1. Aisen P.S. The development of anti-amyloid therapy for Alzheimer's disease from secretase modulators to polymerisation inhibitors. CNS Drugs 2005, 19:989-996.
2. Alzheimer's Association Alzheimer's disease facts and figures. Alzheimers Dement. 2009, 5:234-270.
3. Butterfield D.A., Poon H.F. The senescence-accelerated prone mouse (SAMP8): a model of age-related cognitive decline with relevance to alterations of the gene expression and protein abnormalities in Alzheimer's disease. Exp. Gerontol. 2005, 40:774-783.
4. Chen G.H., Wang Y.J., Wang X.M., Zhou J.N. Accelerated senescence prone mouse-8 shows early onset of deficits in spatial learning and memory in the radial six-arm water maze. Physiol. Behav. 2004, 82:883-890.
5. Chen P.T., Liao T.Y., Hu C.J., Wu S.T., Wang S.S., Chen R.P. A highly sensitive peptide substrate for detecting two Abeta-degrading enzymes: neprilysin and insulin-degrading enzyme. J. Neurosci. Methods 2010, 190:57-62.
6. Cummings J.L. Alzheimer's disease. N. Engl. J. Med. 2004, 351:56-67.
7. Del Valle J., Duran-Vilaregut J., Manich G., Casadesús G., Smith M.A., Camins A., et al. Early amyloid accumulation in the hippocampus of SAMP8 mice. J. Alzheimers. Dis. 2010, 19:1303-1315.
8. D'Hooge R., De Deyn P.P. Applications of the Morris water maze in the study of learning and memory. Brain Res. Brain Res. Rev. 2001, 36:60-90.
9. Fujii T. Herbal factors in the treatment of autoimmunity-related habitual abortion. Vitam. Horm. 2002, 65:333-344.
10. Hagino N. An overview of Kampo Medicine: Toki-Shakuyaku-San (TJ-23). Phytother. Res. 1994, 7:391-394.
11. Haque A., Banik N.L., Ray S.K. New Insights into the Roles of Endolysosomal Cathepsins in the Pathogenesis of Alzheimer's disease: Cathepsin Inhibitors as Potential Therapeutics. CNS Neurol. Disord. Drug. Targets 2008, 7:270-277.
12. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
13. Hatip-Al-Khatib I., Egashira N., Mishima K., Iwasaki K., Iwasaki K., Kurauchi K., et al. Determination of the effectiveness of components of the herbal medicine Toki-Shakuyaku-San and fractions of Angelica acutiloba in improving the scopolamine-induced impairment of rat's spatial cognition in eight-armed radial maze test. J. Pharmacol. Sci. 2004, 96:33-41.
14. Higaki S., Toyomoto T., Morohashi M. Seijo-bofu-to, Jumi-haidoku-to and Toki-shakuyaku-san suppress rashes and incidental symptoms in acne patients. Drugs Exp. Clin. Res. 2002, 28:193-196.
15. Hook V., Schechter I., Demuth H.U., Hook G. Alternative pathways for production of beta-amyloid peptides of Alzheimer's disease. Biol. Chem. 2008, 389:993-1006.
16. Hu Z.Y., Yang Y., Zhou W.X., Zhang Y.X., Shang W.W., Qiao S.Y. JD-30, an active constituent extracted from Danggui Shaoyao San, ameliorates amyloid beta-protein fragment 25-35 induced inhibition of long-term potentiation of CA1 area in rat hippocampal slices. Chin. J. Pharmacol. Toxicol. 2007, 21:185-189.
17. Hu Z.Y., Liu G., Yuan H., Yang S., Zhou W.X., Zhang Y.X., et al. Danggui-Shaoyao-San and its active fraction JD-30 improve Aβ-induced spatial recognition deficits in mice. J. Ethnopharmacol. 2010, 128:365-372.
18. Inanaga K. Aging in brain and mind-drug therapy for patients with behavioral and psychological symptoms of dementia (BPSD). Seishin Shinkeigaku Zasshi 2007, 109:703-708.
19. Kotani N., Oyama T., Sakai I., Hashimoto H., Muraoka M., Ogawa Y., et al. Analgesic effect of a herbal medicine for treatment of primary dysmenorrhea-a double-blind study. Am. J. Chin. Med. 1997, 25:205-212.
20. Li Q., Zhao H.F., Zhang Z.F., Liu Z.G., Pei X.R., Wang J.B., et al. Long-term green tea catechin administration prevents spatial learning and memory impairment in senescence-accelerated mouse prone-8 mice by decreasing Abeta1-42 oligomers and upregulating synaptic plasticity-related proteins in the hippocampus. Neuroscience 2009, 163:741-749.
21. Malito E., Hulse R.E., Tang W.J. Amyloid beta-degrading cryptidases: insulin degrading enzyme, presequence peptidase, and neprilysin. Cell. Mol. Life Sci. 2008, 65:2574-2585.
22. Man S.C., Durairajan S.S., Kum W.F., Lu J.H., Huang J.D., Cheng C.F., et al. Systematic review on the efficacy and safety of herbal medicines for Alzheimer's disease. J. Alzheimers. Dis. 2008, 14:209-223.
23. Mangialasche F., Solomon A., Winblad B., Mecocci P., Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010, 9:702-716.
24. Miners J.S., Baig S., Palmer J., Palmer L.E., Kehoe P.G., Love S. Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 2008, 18:240-252.
25. Miyamoto M. Characteristics of age-related behavioral changes in senescence-accelerated mouse SAMP8 and SAMP10. Exp. Gerontol. 1997, 32:139-148.
26. Mizushima N. Effects of TJ-23 (Toki-shakuyaku-san) on senile dementia. Jpn. Med. Pharm. Soc. Wakan-Yaku 1989, 6:456-457.
27. Mizushima Y., Kan S., Yoshida S., Irie Y., Urata Y. Effect of Choto-san, a Kampo medicine, on impairment of passive avoidance performance in senescence accelerated mouse (SAM). Phytother. Res. 2003, 17:542-545.
28. Neugroschl J., Sano M. Current Treatment and Recent Clinical Research in Alzheimer's Disease. Mt. Sinai J. Med. 2010, 77:3-16.
29. Nomura Y., Okuma Y. Age-related defects in lifespan and learning ability in SAMP8 mice. Neurobiol. Aging 1999, 20:111-115.
30. Nomura Y., Yamanaka Y., Kitamura Y., Arima T., Ohnuki T., Oomura Y., et al. Senescence-accelerated mouse. Neurochemical studies on aging. Ann. N. Y. Acad. Sci. 1996, 786:410-418.
31. Oddo S., Caccamo A., Green K.N., Liang K., Tran L., Chen Y., et al. Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:3046-3051.
32. Okuma Y., Nomura Y. Senescence-accelerated mouse (SAM) as an animal model of senile dementia: pharmacological, neurochemical and molecular biological approach. Jpn. J. Pharmacol. 1998, 78:399-404.
33. Pu F., Mishima K., Egashira N., Akiyoshi Y., Liu A.X., Sano K., et al. Post-ischemic treatment with toki-shakuyaku-san (tang-gui-shao-yao-san) prevents the impairment of spatial memory induced by repeated cerebral ischemia in rats. Am. J. Chin. Med. 2005, 33:475-489.
34. Rofina J.E., Singh K., Skoumalova-Vesela A., van Ederen A.M., van Asten A.J., Wilhelm J., et al. Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine. Amyloid 2004, 11:90-100.
35. Stockley J.H., O'Neill C. Understanding BACE1: essential protease for amyloid-beta production in Alzheimer's disease. Cell. Mol. Life Sci. 2008, 65:3265-3289.
36. Takeda T. Senescence-accelerated mouse (SAM): a biogerontological resource in aging research. Neurobiol. Aging 1999, 20:105-110.
37. Takeda T. Senescence-accelerated mouse (SAM) with special references to neurodegeneration models, SAMP8 and SAMP10 mice. Neurochem. Res. 2009, 34:639-659.
38. Yagi H., Katoh S., Akiguchi I., Takeda T. Age-related deterioration of ability of acquisition in memory and learning in senescence accelerated mouse: SAM-P/8 as an animal model of disturbances in recent memory. Brain Res. 1988, 474:86-93.